Position in PHAT
as of Mar 31, 2026
· filed May 29, 2026
Position Value
$10,276,750
New position
Shares Held
925,000
first reported quarter
Ownership
1.14%
of shares outstanding
% of Portfolio
0.20%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026PERCEPTIVE ADVISORS LLC holds $4,580,660,548 across 68 Biotechnology names. PHAT ranks #53 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PRAX |
Praxis Precision Medicines, Inc.
|
2,035,986 | $655,974,329 | |
| 2 | CELC |
Celcuity Inc.
|
3,127,200 | $356,938,608 | |
| 3 | ASND |
Ascendis Pharma A/S
|
1,531,421 | $350,281,925 | |
| 4 | ROIV |
Roivant Sciences Ltd.
|
8,285,461 | $229,507,269 | |
| 5 | CNTA |
Centessa Pharmaceuticals plc
|
5,258,903 | $208,883,627 | |
| 6 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
2,373,795 | $206,448,951 | |
| 7 | SYRE |
Spyre Therapeutics, Inc.
|
3,783,225 | $190,825,869 | |
| 8 | NUVL |
Nuvalent, Inc.
|
1,580,505 | $161,922,737 |
All Filings in PHAT
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $10,276,750 | 925,000 | Shares | Sole | 2026-05-29 | |
| No filing history on record for this holder in this stock. | ||||||